Eric Dozier
Known title: EVP, Chief People OfficerCIK: 0001955972
Associated companies
Transaction History
| LLY | ▼ Sell | Gift | 216 | $0 | 9/2/2026 | View on chart |
| LLY | ▼ Sell | Gift | 481 | $0 | 2/19/2026 | View on chart |
| LLY | ▲ Buy | Grant | 3,512 | $3.7M | 2/9/2026 | View on chart |
| LLY | ▲ Buy | Option Exercise | 2,858 | $0 | 2/1/2026 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,273 | $1.3M | 2/1/2026 | View on chart |
| LLY | ▲ Buy | Option Exercise | 2,403 | $0 | 3/1/2025 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,066 | $982K | 3/1/2025 | View on chart |
| LLY | ▼ Sell | Gift | 460 | $0 | 2/20/2025 | View on chart |
| LLY | ▲ Buy | Grant | 920 | $799K | 2/10/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 1,534 | $0 | 11/1/2024 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 681 | $558K | 11/1/2024 | View on chart |
| LLY | ▲ Buy | Grant | 1,336 | $985K | 2/12/2024 | View on chart |
| LLY | ▼ Sell | Gift | 408 | $0 | 2/12/2024 | View on chart |
| LLY | ▼ Sell | Gift | 546 | $0 | 8/31/2023 | View on chart |
| LLY | ▲ Buy | Option Exercise | 1,602 | $0 | 3/1/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 714 | $222K | 3/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 1,820 | $628K | 2/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.